UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 86 filers reported holding UROGEN PHARMA LTD in Q2 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $809,862 | +70.4% | 57,806 | +25.9% | 0.00% | – |
| Q2 2023 | $475,272 | -19.2% | 45,920 | -32.0% | 0.00% | – |
| Q1 2022 | $588,000 | +2.6% | 67,486 | +11.9% | 0.00% | – |
| Q4 2021 | $573,000 | -44.5% | 60,289 | -1.7% | 0.00% | – |
| Q3 2021 | $1,032,000 | +20.6% | 61,334 | +9.4% | 0.00% | – |
| Q2 2021 | $856,000 | -17.1% | 56,057 | +5.7% | 0.00% | – |
| Q1 2021 | $1,033,000 | +10.5% | 53,031 | +2.2% | 0.00% | – |
| Q4 2020 | $935,000 | -9.8% | 51,886 | -3.5% | 0.00% | – |
| Q3 2020 | $1,037,000 | -28.2% | 53,753 | -2.8% | 0.00% | – |
| Q2 2020 | $1,444,000 | +67.9% | 55,313 | +14.8% | 0.00% | – |
| Q1 2020 | $860,000 | -46.6% | 48,196 | -0.1% | 0.00% | – |
| Q4 2019 | $1,610,000 | +46.1% | 48,235 | +4.3% | 0.00% | – |
| Q3 2019 | $1,102,000 | -31.0% | 46,243 | +4.0% | 0.00% | – |
| Q2 2019 | $1,598,000 | +279.6% | 44,448 | +398.1% | 0.00% | – |
| Q3 2018 | $421,000 | – | 8,923 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |